5 found
Order:
Disambiguations
Gordon H. Guyatt [4]Gordon Guyatt [1]
  1.  31
    How to generalize efficacy results of randomized trials: recommendations based on a systematic review of possible approaches.Piet N. Post, Hans Beer & Gordon H. Guyatt - 2013 - Journal of Evaluation in Clinical Practice 19 (4):638-643.
  2.  59
    How to teach evidence‐based medicine to teachers: reflections from a workshop experience.Mchammad Hassan Murad, Victor M. Montori, Regina Kunz, Luz M. Letelier, Sheri A. Keitz, Antonio L. Dans, Suzana A. Silva & Gordon H. Guyatt - 2009 - Journal of Evaluation in Clinical Practice 15 (6):1205-1207.
  3.  34
    Assessing Patient Perspectives on Receiving Bad News: A Survey of 1337 Patients With Life-Changing Diagnoses.Reza D. Mirza, Melody Ren, Arnav Agarwal & Gordon H. Guyatt - 2019 - AJOB Empirical Bioethics 10 (1):36-43.
    Background: Guidelines for breaking bad news are largely directed at and validated in oncology patients, based on expert opinion, and neglect those with other diagnoses. We sought to determine whether existing guidelines for breaking bad news, particularly SPIKES, are consistent with patient preferences across patient populations. Methods: Patients from an online community responded to 5 open-ended and 11 Likert-scale questions identifying their preferences in having bad news delivered. Patient participants received a diagnosis of cancer, lupus, amyotrophic lateral sclerosis, multiple sclerosis, (...)
    Direct download (2 more)  
     
    Export citation  
     
    Bookmark   1 citation  
  4.  25
    Biomedical Authorship: Common Misconducts and Possible Scenarios for Disputes.Behrooz Astaneh, Lisa Schwartz & Gordon Guyatt - 2021 - Journal of Academic Ethics 19 (4):455-464.
    Authorship of a scientific paper is important in recognition of one’s work, and in the academic setting, helps in professional promotion. Conflicting views of authorship have led to disputes and debates in many scientific communities. Addressing ethical issues in medical research and publishing, and conforming to the requirements of international organizations and local research ethics boards, has become an essential part of the research endeavor. Ethical issues of biomedical authorship have been a matter of debate for years. Authorship problems may (...)
    Direct download (2 more)  
     
    Export citation  
     
    Bookmark  
  5.  1
    Industry Funding by Itself is Not a Reason for Rating Down Studies for Risk of Bias.João Pedro Lima, Arnav Agarwal & Gordon H. Guyatt - 2024 - Journal of Law, Medicine and Ethics 52 (3):701-703.
    To evaluate how study characteristics and methodological aspects compare based on presence or absence of industry funding, Hughes et al. conducted a systematic survey of randomized controlled trials (RCTs) published in three major medical journals. The authors found industry-funded RCTs were more likely to be blinded, post results on a clinical trials registration database (ClinicalTrials.gov), and accrue high citation counts.1 Conversely, industry-funded trials had smaller sample sizes and more frequently used placebo as the comparator, used a surrogate as their primary (...)
    Direct download (2 more)  
     
    Export citation  
     
    Bookmark